post good oper larg goodwil write-
drove ep loss adj ep exceed
estim consensu compar outlook
report ep loss
includ goodwil impair charg
long-term busi due weak financi perform
industry-wid challeng upsid adj ep estim
led pharmaci servic pbm retail/ltc slightli
weaker lower interest expens tax rate attribut
beat time pbm earn interest tax
rais adj ep outlook midpoint
call highlight progress aet
deal updat expect deal close late
vs latter half discuss challeng
remain optimist long-term growth potenti assist
live cite plan improv perform relat
on-going debat around drug pricing/reb final quantifi
expect retain rebat adj ep
help eas investor concern rebat go away could hurt
earn significantli rais adj ep
estim resp
leav price target unchang base price-to-earnings
updat pbm sell season cite gross win
fewer rfp opportun prior sell season
net win complet client
renew in-lin previou year retent rate
slightli higher prior year includ exclud
fep contract renew extend
despit pressur near-term goodwil impair
charg attribut rise interest rate lower market
comp lower-than-expect financi perform
manag highlight plan improv perform includ
put place new manag team implement initi
enhanc servic level target client retent
higher better serv assist independ live
market increas penetr initi
system-wid cost improv effort target cost
save opportun next year
seem posit well medicar part growth
though acknowledg competit landscap remain
benchmark region within de minimu allow
retain current low-income-subsidi auto assigne
qualifi new auto-assigne region growth part
also help store traffic store volum quarter
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
adjust exclud intang amort one-tim item quarterli ep
may add due share repurchas
compani prioriti stock list
compani data secur llc estim reuter
earn outlook rais narrow adjust ep guidanc new rang
prior outlook fy net revenu growth outlook lower slightli
outlook enterpris adjust oper profit growth narrow
versu previous consolid guidanc
metric includ tax rate unchang adjust net interest expens billion
billion previous retail/ltc segment adjust oper profit expect declin
low singl digit unchang net revenu growth previous same-
store sale compstore growth same-stor adjust script growth
stronger compstore outlook partli reflect solid compstore growth
pharmaci compstore guidanc same-stor script
growth front-end compstore bp neg impact earlier holiday
year pharmaci servic segment oper profit growth project low-
mid-singl digit rang unchang revenu growth total adjust
claim billion unchang
offer adjust ep outlook net revenu growth yr/yr
enterpris adjust oper profit declin retail/ltc segment adjust oper
profit project declin mid-singl digit revenu growth same-stor
sale growth same-stor adjust script growth pharmaci
servic segment adjust oper profit expect flat low singl digit net
revenu growth
retain rebat million final quantifi expect retain rebat
million note pass along rebat compar past commentari
show declin custom gener either use health plan
lower premium pass member lower drug cost clear million
relat commerci member sinc part requir pass along rebat
medicar plan also note drug lower rebat higher increas price drug
larger rebat agre seem logic sinc drug without rebat gener exclus
market posit sinc less competit includ formulari believ clariti
complet quarter disclosur help retir debat around rebat
sourc rise drug price potenti risk sinc adjust ep impact
aetna transact progress expect depart justic doj reach decis
shortli sinc state approv still like requir addit time doj approv
expect close transact late seem like expect doj decid
attempt block acquisit aet within next month perhap two would
comment discuss perhap need sell part aet part busi
identifi earli potenti overlap compani note would stop deal
close aet million part live like gener billion revenu million
pre-tax margin would expect could gener proce billion sale
expect deal close note certain
summari quarterli incom statement well fargo million except y/yfisc year end decemb changeselect commentarypharmaci servic adj claim rose pharmacy/ ebitda yr/yr pharmaci servic retail pharmacy/ interest expens goodwil impair charg interest expens relat aet incom tax continu discontinu oper net loss attribut non-controlling incom attribut guidanc continu averag share total compstore pharmaci compstore front store compstore million unless otherwis profit ep servic pbm adjust prescript choic penetr dispens rate profit profit profit profit per adjust per adjust pharmaci long-term adj retail prescript gener dispens store sale pharmaci store sale front profit profit health servic
compani report secur llc
note adjust ep exclud intang amort one-tim item
compani report secur llc
compani report secur llc
ep adjust ep revenu billion pharmaci servicesretail pharmaci profit yoy growth corp
compani report secur llc
compani report secur llc
compani report secur llc
profit marginpharmaci servic gpmretail pharmaci profit marginpharmaci servic opmretail pharmaci profit million pharmaci servic oper profitretail pharmaci oper profit servic
compani report secur llc
note chang adjust claim methodolog better reflect retail prescript adjust
claim mail penetr rate prior shown base old methodolog
compani report secur llc
compani report secur llc
note chang adjust claim methodolog better reflect retail prescript adjust
claim prior shown base old methodolog
compani report secur llc
compani report secur llc
compani report secur llc
store sale compstore growthpharmaci sssfront store ssstotal revenu billion pharmacyfront claim million adjust claimsgener dispens rate
health quarterli incom statement million except per share dec expens tax continu discontinu oper net loss attribut non-controlling incom attribut averag continu tax servic segment adjust claim volum gener dispens rate ebitda per adj oper oper profit margin retail pharmacy/ltc segment adj retail prescript fill gener dispens rate net oper oper profit margin margin analysisgross changenet secur llc estim compani reportsnot quarter may add due share repurchas and/or restat
exhibit balanc sheet statement
health balanc sheet health statement flow millionsestimatedestim flow oper activ current assetsnet cash receiv incom tax non-cash incom oper asset current receiv current current equip asset long-term cash provid oper sharehold equiti flow invest activ current liabil addit properti sale-lease-back discount net cash acquir short-term sale matur short-term portion long-term sale dispos current cash provid invest incom flow financ activ long-term decreas short-term non-controlling debt assum liabil long-term long-term exercis stock held tax benefit stock-bas common cash provid financ sharehold liabil sharehold chang cash cash equival restrict chang restrict secur llc estim compani report cash equival cash equival secur llc estim compani report health servic
price target nc
price target base price-to-earnings multipl time ep estim risk
includ continu need capit spend maintain store grow new busi compet
custom supplier increas price transpar competit price pressur abil
complet success integr plan acquisit aet
rate share outperform believ posit weather chang pbm/retail
pharmaci busi increas use narrow network price transpar competit
pressur believ vertic structur abil dispens drug channel posit
futur also plan acquisit aet creat integr healthcar platform better
posit competit threat
headquart woonsocket rhode island one largest pharmaci dispens
pharmaci benefit manag countri leader retail pharmaci oper store
unit state puerto rico brazil also leader dispens pharmaceut
institut omnicar busi acquir home coram
busi acquir mail via caremark acquir
recent acquisit in-stor pharmaci also provid greater distribut network
gener approxim billion revenu increas year-over-year
billion net earn
